S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:ALNY

Alnylam Pharmaceuticals News Headlines

$143.39
+6.02 (+4.38 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$133.08
Now: $143.39
$143.42
50-Day Range
$137.37
MA: $158.30
$175.69
52-Week Range
$84.97
Now: $143.39
$178.41
Volume491,300 shs
Average Volume793,167 shs
Market Capitalization$16.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47

Headlines

Alnylam Pharmaceuticals (NASDAQ ALNY) News Headlines Today

Source:
SourceHeadline
Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Guggenheim to "Neutral"Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Guggenheim to "Neutral"
marketbeat.com - February 22 at 7:34 AM
3 Oversold Stocks That Could Bounce Back in a Hurry (ALNY)3 Oversold Stocks That Could Bounce Back in a Hurry (ALNY)
marketbeat.com - September 23 at 1:26 PM
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Announce Earnings of -$1.73 Per ShareAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Expected to Announce Earnings of -$1.73 Per Share
americanbankingnews.com - March 4 at 12:34 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.3%Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.3%
americanbankingnews.com - March 3 at 7:18 PM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns "Neutral" Rating from GuggenheimAlnylam Pharmaceuticals (NASDAQ:ALNY) Earns "Neutral" Rating from Guggenheim
americanbankingnews.com - March 1 at 10:27 AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by GuggenheimAlnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Guggenheim
americanbankingnews.com - February 22 at 8:49 AM
Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare ConferenceAlnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 18 at 5:02 PM
Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess SalesIronwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales
msn.com - February 18 at 12:01 PM
Alnylam Pharmaceuticals (ALNY) Hold Rating Reiterated at Royal Bank of CanadaAlnylam Pharmaceuticals' (ALNY) Hold Rating Reiterated at Royal Bank of Canada
americanbankingnews.com - February 15 at 12:56 AM
Barclays Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $196.00Barclays Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $196.00
americanbankingnews.com - February 12 at 10:09 AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $235.00 at HC WainwrightAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $235.00 at HC Wainwright
americanbankingnews.com - February 12 at 10:09 AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $180.00 at Needham & Company LLCAlnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $180.00 at Needham & Company LLC
americanbankingnews.com - February 12 at 9:37 AM
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $206.00 at Morgan StanleyAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $206.00 at Morgan Stanley
americanbankingnews.com - February 12 at 9:37 AM
Citigroup Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) to NeutralCitigroup Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) to Neutral
americanbankingnews.com - February 12 at 9:00 AM
Alnylam Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationAlnylam Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 11 at 5:52 PM
Recap: Alnylam Pharmaceuticals Q4 EarningsRecap: Alnylam Pharmaceuticals Q4 Earnings
benzinga.com - February 11 at 5:21 PM
Alnylams long history, and promising future, of innovationAlnylam's long history, and promising future, of innovation
bizjournals.com - February 11 at 5:21 PM
Alnylam Pharmaceuticals Inc (ALNY) Q4 2020 Earnings Call TranscriptAlnylam Pharmaceuticals Inc (ALNY) Q4 2020 Earnings Call Transcript
fool.com - February 11 at 1:49 PM
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period ActivityAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
businesswire.com - February 11 at 12:20 PM
Alnylam Pharmaceuticals Q4 misses beat, provides 2021 guidance and updates on recent activityAlnylam Pharmaceuticals Q4 misses beat, provides 2021 guidance and updates on recent activity
seekingalpha.com - February 11 at 11:34 AM
Preview: Alnylam Pharmaceuticalss EarningsPreview: Alnylam Pharmaceuticals's Earnings
benzinga.com - February 10 at 12:48 PM
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Could Be 36% Below Their Intrinsic Value EstimateAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Could Be 36% Below Their Intrinsic Value Estimate
finance.yahoo.com - February 5 at 7:55 AM
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial ResultsAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - January 28 at 1:12 PM
Vir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up AgainVir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up Again
finance.yahoo.com - January 27 at 12:00 PM
First Week of September 17th Options Trading For Alnylam Pharmaceuticals (ALNY)First Week of September 17th Options Trading For Alnylam Pharmaceuticals (ALNY)
nasdaq.com - January 15 at 1:15 PM
Alnylam sets ambitious goal: Be among top 5 most-valuable biotechs by 2025Alnylam sets ambitious goal: Be among top 5 most-valuable biotechs by 2025
bizjournals.com - January 10 at 9:11 PM
Alnylam Launches "Alnylam P5x25" Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five YearsAlnylam Launches "Alnylam P5x25" Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
finance.yahoo.com - January 10 at 4:10 PM
Alnylam Pharmaceuticals Logs Another Clinical Win For Its Amyloidosis ProgramAlnylam Pharmaceuticals Logs Another Clinical Win For Its Amyloidosis Program
seekingalpha.com - January 8 at 6:42 PM
Alnylam Pharmaceuticals, Inc.: Alnylam Reports Positive Vutrisiran Data; Maintaining Our $150 Fair Value EstimateAlnylam Pharmaceuticals, Inc.: Alnylam Reports Positive Vutrisiran Data; Maintaining Our $150 Fair Value Estimate
finance.yahoo.com - January 8 at 3:38 AM
Alnylam: HELIOS-A Phase 3 Study Of Vutrisiran Met Primary And Secondary Endpoints - Quick FactsAlnylam: HELIOS-A Phase 3 Study Of Vutrisiran Met Primary And Secondary Endpoints - Quick Facts
nasdaq.com - January 7 at 12:28 PM
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with PolyneuropathyAlnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
finance.yahoo.com - January 7 at 7:27 AM
Get Ready For Health Care Stocks to Go Wild. How to Play Them.Get Ready For Health Care Stocks to Go Wild. How to Play Them.
barrons.com - January 5 at 7:14 AM
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare ConferenceAlnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 8:35 PM
Update: Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gained 52% In The Last Five YearsUpdate: Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gained 52% In The Last Five Years
finance.yahoo.com - December 22 at 8:33 AM
Is ALNY A Good Stock To Buy Now According To Hedge Funds?Is ALNY A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 20 at 8:13 PM
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D DayAlnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
finance.yahoo.com - December 15 at 10:16 AM
Global Antisense & RNAi Therapeutics Market Report 2020-2030 Featuring GlaxoSmithKline, Sanofi, Gene Signal & Acuitas Therapeutics Among OthersGlobal Antisense & RNAi Therapeutics Market Report 2020-2030 Featuring GlaxoSmithKline, Sanofi, Gene Signal & Acuitas Therapeutics Among Others
benzinga.com - December 8 at 10:24 PM
CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of HereditaryCENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary
bloomberg.com - December 8 at 5:23 PM
Alnylam to Webcast Virtual R&D DayAlnylam to Webcast Virtual R&D Day
finance.yahoo.com - December 8 at 12:23 PM
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents on Investor Event ASH 2020 Conference Call TranscriptRegeneron Pharmaceuticals, Inc. (REGN) Management Presents on Investor Event ASH 2020 Conference Call Transcript
seekingalpha.com - December 8 at 1:27 AM
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Companys Approved TherapiesAlnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company's Approved Therapies
benzinga.com - December 7 at 9:41 AM
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved TherapiesAlnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
finance.yahoo.com - December 7 at 9:41 AM
Why Is Alnylam (ALNY) Down 6% Since Last Earnings Report?Why Is Alnylam (ALNY) Down 6% Since Last Earnings Report?
finance.yahoo.com - December 5 at 4:07 PM
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
finance.yahoo.com - December 3 at 6:11 PM
Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran)Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran)
finance.yahoo.com - December 3 at 6:11 PM
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate LevelsPANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
finance.yahoo.com - December 3 at 6:11 PM
Alnylam Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALNYAlnylam Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALNY
nasdaq.com - December 1 at 5:29 PM
3 Reasons Alnylam Is a Top Biotech Stock to Buy Right Now3 Reasons Alnylam Is a Top Biotech Stock to Buy Right Now
nasdaq.com - November 30 at 4:44 PM
Biotech Stock Roundup: REGNs Cocktail Gets EUA, GILD & AMGN Provide Updates & MoreBiotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More
finance.yahoo.com - November 25 at 2:18 PM
Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor ConferenceAlnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
finance.yahoo.com - November 25 at 9:17 AM
Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra ...Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra ...
businesswire.com - November 24 at 8:31 AM
FDA Approves Alnylams Oxlumo To Treat Rare Metabolic DisorderFDA Approves Alnylam's Oxlumo To Treat Rare Metabolic Disorder
nasdaq.com - November 24 at 8:31 AM
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.